Free Trial
NASDAQ:AKBA

Akebia Therapeutics (AKBA) Stock Price, News & Analysis

Akebia Therapeutics logo
$2.92 +0.07 (+2.28%)
As of 11:45 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Akebia Therapeutics Stock (NASDAQ:AKBA)

Advanced

Key Stats

Today's Range
$2.85
$2.94
50-Day Range
$2.68
$3.79
52-Week Range
$1.25
$4.08
Volume
764,382 shs
Average Volume
4.03 million shs
Market Capitalization
$772.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.75
Consensus Rating
Moderate Buy

Company Overview

Akebia Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
69th Percentile Overall Score

AKBA MarketRank™: 

Akebia Therapeutics scored higher than 69% of companies evaluated by MarketBeat, and ranked 307th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Akebia Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 4 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Akebia Therapeutics has a consensus price target of $6.75, representing about 131.1% upside from its current price of $2.92.

  • Amount of Analyst Coverage

    Akebia Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Akebia Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Akebia Therapeutics are expected to grow in the coming year, from ($0.30) to ($0.14) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Akebia Therapeutics is -17.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Akebia Therapeutics is -17.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Akebia Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.32% of the outstanding shares of Akebia Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Akebia Therapeutics has a short interest ratio ("days to cover") of 7.1.
  • Change versus previous month

    Short interest in Akebia Therapeutics has recently increased by 1.00%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Akebia Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Akebia Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.32% of the outstanding shares of Akebia Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Akebia Therapeutics has a short interest ratio ("days to cover") of 7.1.
  • Change versus previous month

    Short interest in Akebia Therapeutics has recently increased by 1.00%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Akebia Therapeutics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Akebia Therapeutics this week, compared to 4 articles on an average week.
  • Search Interest

    52 people have searched for AKBA on MarketBeat in the last 30 days. This is an increase of 206% compared to the previous 30 days.
  • MarketBeat Follows

    5 people have added Akebia Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Akebia Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.00% of the stock of Akebia Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 33.92% of the stock of Akebia Therapeutics is held by institutions.

  • Read more about Akebia Therapeutics' insider trading history.
Receive AKBA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Akebia Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

AKBA Stock News Headlines

Arizona-made nanochips the new millionaire maker?
George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.tc pixel
See More Headlines

AKBA Stock Analysis - Frequently Asked Questions

Akebia Therapeutics' stock was trading at $1.90 at the start of the year. Since then, AKBA shares have increased by 53.7% and is now trading at $2.9210.

Akebia Therapeutics, Inc. (NASDAQ:AKBA) released its quarterly earnings data on Thursday, May, 8th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.06. The biopharmaceutical company earned $57.34 million during the quarter, compared to the consensus estimate of $44.88 million.
Read the conference call transcript
.

Akebia Therapeutics' top institutional shareholders include Assenagon Asset Management S.A. (0.16%). Insiders that own company stock include John P Butler, Steven Keith Burke, Michel Dahan, Nicole R Hadas, David A Spellman, Erik Ostrowski, Nicholas Grund and Richard C Malabre.
View institutional ownership trends
.

Shares of AKBA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Akebia Therapeutics investors own include Novavax (NVAX), NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD), Intel (INTC) and Exxon Mobil (XOM).

Company Calendar

Last Earnings
5/08/2025
Today
10/09/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AKBA
CIK
1517022
Employees
430
Year Founded
2007

Price Target and Rating

High Price Target
$8.00
Low Price Target
$6.00
Potential Upside/Downside
+134.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.17)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$69.41 million
Net Margins
-17.91%
Pretax Margin
-17.91%
Return on Equity
N/A
Return on Assets
-13.47%

Debt

Debt-to-Equity Ratio
1.61
Current Ratio
1.98
Quick Ratio
1.84

Sales & Book Value

Annual Sales
$160.18 million
Price / Sales
4.76
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.23) per share
Price / Book
-12.50

Miscellaneous

Outstanding Shares
265,140,000
Free Float
257,191,000
Market Cap
$762.28 million
Optionable
Optionable
Beta
0.68

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:AKBA) was last updated on 10/9/2025 by MarketBeat.com Staff
From Our Partners